GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (NAS:APLS) » Definitions » Shiller PE Ratio

APLS (Apellis Pharmaceuticals) Shiller PE Ratio : (As of Mar. 04, 2025)


View and export this data going back to 2017. Start your Free Trial

What is Apellis Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Apellis Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Apellis Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apellis Pharmaceuticals Shiller PE Ratio Chart

Apellis Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Apellis Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Apellis Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Apellis Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Apellis Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Apellis Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Apellis Pharmaceuticals's Shiller PE Ratio falls into.



Apellis Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Apellis Pharmaceuticals's E10 for the quarter that ended in Dec. 2024 is calculated as:

For example, Apellis Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-0.29/133.1571*133.1571
=-0.290

Current CPI (Dec. 2024) = 133.1571.

Apellis Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201409 -0.137 100.428 -0.182
201412 -0.149 99.070 -0.200
201506 -0.244 100.684 -0.323
201509 -1.724 100.392 -2.287
201512 -0.454 99.792 -0.606
201606 -0.281 101.688 -0.368
201609 -0.399 101.861 -0.522
201612 -0.366 101.863 -0.478
201703 -0.500 102.862 -0.647
201706 -0.670 103.349 -0.863
201709 -0.300 104.136 -0.384
201712 -0.363 104.011 -0.465
201803 -0.430 105.290 -0.544
201806 -0.610 106.317 -0.764
201809 -0.640 106.507 -0.800
201812 -0.650 105.998 -0.817
201903 -0.870 107.251 -1.080
201906 -1.120 108.070 -1.380
201909 -1.100 108.329 -1.352
201912 -2.110 108.420 -2.591
202003 -2.290 108.902 -2.800
202006 -1.570 108.767 -1.922
202009 -1.790 109.815 -2.170
202012 1.060 109.897 1.284
202103 -2.320 111.754 -2.764
202106 -2.720 114.631 -3.160
202109 -2.280 115.734 -2.623
202112 -1.530 117.630 -1.732
202203 -1.420 121.301 -1.559
202206 -1.460 125.017 -1.555
202209 -1.750 125.227 -1.861
202212 -1.500 125.222 -1.595
202303 -1.560 127.348 -1.631
202306 -1.020 128.729 -1.055
202309 -1.170 129.860 -1.200
202312 -0.730 129.419 -0.751
202403 -0.540 131.776 -0.546
202406 -0.300 132.554 -0.301
202409 -0.460 133.029 -0.460
202412 -0.290 133.157 -0.290

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Apellis Pharmaceuticals  (NAS:APLS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Apellis Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Apellis Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Apellis Pharmaceuticals Business Description

Traded in Other Exchanges
Address
100 Fifth Avenue, Waltham, MA, USA, 02451
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
Executives
Mark Jeffrey Delong officer: Senior Vice President 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Adam J. Townsend officer: See Remarks C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
David O. Watson officer: General Counsel 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Pascal Deschatelets officer: Chief Operating Officer 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Karen Lewis officer: Chief People Officer APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Jeffrey Eisele officer: See Remarks APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Nur Nicholson officer: Chief Technical Officer APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
Timothy Eugene Sullivan officer: Chief Financial Officer 800 BOYLSTON ST., SUITE 3310, PRUDENTIAL TOWER C/O AJU IB INVESTMENT, BOSTON MA 02199
Cedric Francois director, 10 percent owner, officer: Chief Executive Officer 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
James George Chopas officer: See Remarks 950 WINTER STREET, WALTHAM MA 02451
Caroline Baumal officer: Chief Medical Officer C/O APELLIS PHARMACEUTICALS, INC., 100 5TH AVENUE, 3RD FLOOR, WALTHAM MA 02451
A. Sinclair Dunlop director C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Lukas Scheibler officer: See Remarks C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014
Alec Machiels director 505 PARK AVENUE, 21ST FLOOR, NEW YORK NY 10022
Federico Grossi officer: See Remarks C/O APELLIS PHARMACEUTICALS, INC., 6400 WESTWIND WAY, SUITE A, CRESTWOOD KY 40014